MarshyOSScientific due diligence studio

Sample report  /  2 pages  /  public sources only

In 2019 the headline said it worked. Read what the record said.

Aducanumab, checked claim by claim, the way we would hand it to an investment committee. What held, what didn't, what nobody could establish, and the questions we would have put to the sponsor before a penny moved. Ten minutes to read.

Send me the 2 pages
PAGE 2 / 2What nobody could establish
Questions for the sponsor
1. Which pre-specified analysis supports efficacy across both trials?
PAGE 1 / 2MARSHYOS
Aducanumab: what the record supportedCONTESTEDThe verdict, in one paragraph
Claims that heldEMERGE met its primary endpoint at the high dose. [1]Claims that didn't

Inside the two pages

The verdict, in one paragraphp. 1
Claims that held, with sourcesp. 1
Claims that didn't, and whyp. 1
What nobody could establishp. 2
The questions we'd put to the sponsorp. 2

Why this asset? Famous enough that you know the headline. Public enough that every line can be checked. Close enough to a live deal that the method carries straight over to yours.

Get the 2 pages.

The PDF opens as soon as you send. No newsletters, no sequences.

Same two pages. Your asset. Before you sign.

Book an evidence session